Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.40
+0.01 (+1.28%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $2.8M · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$47M
P/E
N/A
•EV/EBITDA
16.7x
↑ROE
-13.8%
↓Gross Margin
41.7%
↓Debt/Equity
0.46
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.0%
FCF CAGR
—
FCF margin
-8.7%
FCF / Net income
0.66x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $30.1M · net income $-4.0M · FCF $-2.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $30.1M | $30.1M | $28.3M | $28.9M | $33.0M |
| Net Income | $-4.0M | $-4.0M | $-3.3M | $293211.00 | $10.0M |
| EBITDA | $3.5M | $3.5M | $2.2M | $7.0M | $20.7M |
| EPS | -0.03 | -0.03 | -0.03 | — | 0.09 |
| Gross Margin | 41.7% | 41.7% | 39.4% | 46.4% | 57.0% |
| Operating Margin | 4.3% | 4.3% | 5.2% | 13.7% | 29.6% |
| Net Margin | -13.2% | -13.2% | -11.7% | 1.0% | 30.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.46 | 0.46 | 0.35 | 0.35 | 0.55 |
| Current Ratio | 1.32 | 1.32 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.6M | $-2.6M | $2.8M | $5.5M | $4.3M |
| Returns | |||||
| ROE | -13.8% | -13.8% | -10.6% | 0.9% | 29.5% |
| Valuation | |||||
| P/E | — | — | — | — | 6.33 |
| EV/EBITDA | 16.71 | 16.71 | 38.14 | 8.16 | 4.09 |
| P/B | 1.66 | 1.66 | 2.41 | 1.36 | 2.05 |
| Growth & Yield | |||||
| Revenue Growth | 6.5% | 6.5% | -2.1% | -12.4% | — |
| EPS Growth | 0.0% | 0.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+71.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → -0.03
Residual
+71.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.